Lumida
/CRDF
⌘K
Cardiff Oncology Inc

Cardiff Oncology Inc

CRDF
$1.21USD+0.00%+0.00 today

MARKET CAP

94.1M

P/E (TTM)

FWD P/E

DAY RANGE

$1 – $1

52W RANGE

$1
$3

AI Summary

Stalk
TrimMedium

CRDF remains in Stage 4 decline with medium-term bearish bias—execution should focus on trimming into rallies around the declining 9/21 EMA zone and prior consolidation highs. Short-term timing is neutral amid extreme oversold conditions, suggesting deferred engagement until relief bounces stall.

  • Onvansertib shows 64% ORR in 30 mg cohort vs 33% in control arm.
  • Strategic shift to first-line RAS-mutated mCRC backed by FDA guidance.
  • Q4 cash burn of ~$10.3M per quarter strains the $91.7M runway.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$359,000$386,000$488,000$683,000$593,000
YoY %-1.9%+7.5%+26.4%+40.0%-13.2%
P / Sales653.4x167.2x140.1x302.8x316.7x
EV / Sales645.6x150.3x120.1x248.3x315.1x
Gross Profit, Adj.$359,000$386,000$488,000$683,000$593,000
YoY %-1.9%+7.5%+26.4%+40.0%-13.2%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit645.6x150.3x120.1x248.3x315.1x
EBITDA, Adj.$-28.4M$-39.7M$-45.0M$-48.2M$-48.6M
YoY %-52.5%-39.6%-13.5%-7.2%-0.7%
Margin %-7912.0%-10276.2%-9224.2%-7064.0%-8194.9%
EV / EBITDA-8.2x-1.5x-1.3x-3.5x-3.8x
EBIT$-28.9M$-39.9M$-45.4M$-48.7M$-49.0M
YoY %-51.2%-38.3%-13.8%-7.1%-0.6%
Margin %-8037.6%-10337.3%-9305.7%-7123.1%-8256.3%
EV / EBIT-8.0x-1.5x-1.3x-3.5x-3.8x
Net Income$-28.3M$-38.7M$-41.5M$-45.5M$-45.9M
YoY %-25.3%-36.8%-7.1%-9.6%-0.9%
Net Margin-7887.2%-10033.2%-8496.9%-6655.2%-7736.3%
EPS (GAAP)-$0.73-$0.89-$0.93-$0.95-$0.69
YoY %+32.4%-21.9%-4.5%-2.2%+27.4%